摘要
目的比较门冬胰岛素与生物合成人胰岛素治疗新诊断Ⅱ型糖尿病的临床疗效。方法将新诊断的96例Ⅱ型糖尿病患者随机均分为2组,分别为门冬胰岛素(治疗)组和生物合成人胰岛素(对照)组。患者分别在每日餐前给予皮下注射门冬胰岛素和生物合成人胰岛素,且均每晚定时皮下注射一次甘精胰岛素。比较2组患者血糖、低血糖事件、胰岛素用量的差异。结果用药后2组餐前及餐后的血糖含量均明显降低,且门冬胰岛素组餐前、餐后血糖均低于生物合成人胰岛素组;门冬胰岛素组患者低血糖发生次数低于生物合成人胰岛素组,差异有统计学意义;但2组胰岛素用量无显著差异。结论门冬胰岛素能够更好地控制Ⅱ型糖尿病的血糖,对Ⅱ型糖尿病的治疗更加有效。
Objective To compare the clinical efficacy between insulin aspart and biosyn- thetic human insulin in the treatment of newly diagnosed type 2 diabetes. Methods Ninety-six newly diagnosed type 2 diabetic patients were randomly divided into insulin aspart group （treatment group, n = 48） and biosynthetic human insulin group （control group, n = 48）. The patients re- ceived subcutaneous injection of insulin aspart or biosynthetic human insulin before daily meals, and they were treated with insulin glargine at the bedtime. The blood sugar levels, incidence of hypoglycemic episodes and the dosage of insulin were compared between the two groups. Results After administration of the drugs, the blood sugar levels were significantly reduced, and the blood sugar levels was lower in insulin aspart group than in the control group. The incidence of hypoglycemia in the treatment group was lower than in the control group, and the difference was statistically significant. The dosage of insulin showed no significant difference in the two groups. Conclusion Insulin aspart was better in the control of blood sugar levels and more effective in the treatment of patients with type 2 diabetes.
出处
《实用临床医药杂志》
CAS
2012年第21期144-146,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11220135)
